Indoramin
Brand names: Doralese
Indoramin is a selective alpha-1 adrenoceptor antagonist used to relieve voiding symptoms in benign prostatic hyperplasia and, less commonly, in hypertension.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It selectively blocks post-synaptic alpha-1 adrenoceptors, relaxing smooth muscle in the bladder neck and prostate to reduce outflow obstruction.
Prescribing in practice
- It is markedly sedating and can impair driving and skilled-task performance, particularly on initiation and when combined with alcohol or other CNS depressants.
- It may cause first-dose and postural hypotension, so introduce it cautiously, especially in older patients.
- Avoid in patients with established heart failure and use caution in Parkinson's disease and depression, in line with the SPC.
Monitoring
Monitor blood pressure (including lying and standing where relevant) and review symptom response and tolerability after initiation and dose changes.
Counselling the patient
- This medicine can make you drowsy; do not drive or operate machinery until you know how it affects you, and avoid alcohol.
- Rise slowly from sitting or lying to reduce dizziness.
- Report fainting, palpitations or persistent drowsiness.
Evidence & guidelines
Alpha-1 blockade is an established option for symptomatic benign prostatic hyperplasia, supported by NICE guidance on lower urinary tract symptoms in men.
Reference: NICE NG134; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.